D. Bozyczko‐Coyne

发表

Target identification and validation in drug discovery: the role of proteomics.

Karla K Kopec, D. Bozyczko‐Coyne, Michael Williams, 2005, Biochemical pharmacology.

CEP‐1347 (KT7515), an Inhibitor of JNK Activation, Rescues Sympathetic Neurons and Neuronally Differentiated PC12 Cells from Death Evoked by three Distinct Insults

N. Neff, L. Greene, D. Bozyczko‐Coyne, 1999, Journal of neurochemistry.

CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.

D. Bozyczko‐Coyne, M. Leist, D. Flood, 2005, European journal of pharmacology.

Mixed lineage kinase activity of indolocarbazole analogues.

D. Bozyczko‐Coyne, C. Murakata, T. Angeles, 2002, Bioorganic & medicinal chemistry letters.

Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells

D. Bozyczko‐Coyne, A. Maroney, G. Ghadge, 2004, Brain Research.

Laboratory Notebooks and Data Storage

D. Bozyczko‐Coyne, Michael Williams, Bruce D. Dorsey, 2020, Current Protocols Essential Laboratory Techniques.

The calcium-activated protease calpain I and ischemia-induced neurodegeneration.

D. Bozyczko‐Coyne, R. Siman, J. Roberts-Lewis, 1996, Advances in neurology.

CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities

D. Bozyczko‐Coyne, E. Duzic, M. Williams, 2012, Journal of Pharmacology and Experimental Therapeutics.

Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system.

D. Bozyczko‐Coyne, R. W. Scott, C. Spais, 1996, The Biochemical journal.

Targeting the JNK pathway for therapeutic benefit in CNS disease.

D. Bozyczko‐Coyne, R. Hudkins, M. Saporito, 2002, Current drug targets. CNS and neurological disorders.

IGF‐I Supports the Survival and/or Differentiation of Multiple Types of Central Nervous System Neurons

N. Neff, D. Bozyczko‐Coyne, M. Glicksman, 1993, Annals of the New York Academy of Sciences.

Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I.

D. Bozyczko‐Coyne, J. Mallamo, G. Wells, 1997, Journal of medicinal chemistry.

Immunolocalization of caspase proteolysis in situ: evidence for widespread caspase-mediated apoptosis of neurons and glia in the postnatal rat brain

D. Bozyczko‐Coyne, R. Bhat, S. Meyer, 1999, Neuroscience.

Xanthene derived potent nonpeptidic inhibitors of recombinant human calpain I

D. Bozyczko‐Coyne, J. Mallamo, S. Chatterjee, 1996 .

A rapid fluorometric assay to measure neuronal survival in vitro

N. Neff, D. Bozyczko‐Coyne, B. McKenna, 1993, Journal of Neuroscience Methods.

Subsite requirements for peptide aldehyde inhibitors of human calpain I

Eric C. Griffith, D. Bozyczko‐Coyne, M. Ator, 1997 .

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.

D. Bozyczko‐Coyne, A. Fedorov, E. Fedorov, 2008, Journal of Medicinal Chemistry.

CEP‐1347/KT‐7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ‐induced cortical neuron apoptosis

D. Bozyczko‐Coyne, P. Dobrzanski, R. Scott, 2001, Journal of neurochemistry.

The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.

D. Bozyczko‐Coyne, V. R. Marcy, M. Gasior, 2009, Sleep.

Inhibition of microglial inflammation by the MLK inhibitor CEP‐1347

Thomas Hartung, Pietro Ghezzi, Marcel Leist, 2005, Journal of neurochemistry.

D-amino acid containing, high-affinity inhibitors of recombinant human calpain I.

D. Bozyczko‐Coyne, J. Mallamo, S. Chatterjee, 1998, Journal of medicinal chemistry.

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.

D. Bozyczko‐Coyne, Michael Williams, P. Waldmeier, 2006, Biochemical pharmacology.

Protein Tyrosine Phosphatases Are Up-regulated and Participate in Cell Death Induced by Polyglutamine Expansion*

D. Bozyczko‐Coyne, R. Scott, M. Savage, 2002, Journal of Biological Chemistry.

Prolonged Calpain‐mediated Spectrin Breakdown Occurs Regionally Following Experimental Brain Injury in the Rat

D. Bozyczko‐Coyne, T. Mcintosh, K. Saatman, 1996, Journal of neuropathology and experimental neurology.

Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease

D. Bozyczko‐Coyne, D. Flood, M. Savage, 2006, Neurobiology of Aging.

Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat

D. Bozyczko‐Coyne, Michael Williams, W. Dement, 2006, Pharmacology Biochemistry and Behavior.

6.08 – Neurodegeneration

D. Bozyczko‐Coyne, M. Williams, 2007 .

Behavioral responses of dopamine β-hydroxylase knockout mice to modafinil suggest a dual noradrenergic–dopaminergic mechanism of action

Heather A. Mitchell, M. Epstein, D. Bozyczko‐Coyne, 2008, Pharmacology Biochemistry and Behavior.

The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.

D. Bozyczko‐Coyne, Michael Williams, K. Spiegel, 2007, Biochemical pharmacology.

A sensitive, continuously recording fluorogenic assay for calpain.

D. Bozyczko‐Coyne, R. Siman, M. Ator, 1998, Biochemical and Biophysical Research Communications - BBRC.

Potent fluoromethyl ketone inhibitors of recombinant human calpain I

D. Bozyczko‐Coyne, J. Mallamo, G. Wells, 1996 .